Medicus Pharma will focus its SkinJect clinical development exclusively on patients with Gorlin syndrome, a rare disease causing multiple basal cell carcinoma lesions, and will stop development for sporadic basal cell carcinoma. This decision follows FDA feedback and aligns with the company's strategy to prioritize programs with the best risk-adjusted potential. The FDA considers basal cell carcinoma in Gorlin syndrome similar to sporadic cases but noted the overall prevalence exceeds thresholds for certain designations. Medicus plans to continue discussions with the FDA and build on prior Phase 2 study results, advancing a Phase 2b trial in Gorlin syndrome patients.
Medicus Pharma's focus on SkinJect development for Gorlin syndrome patients is presented with Pluang's Health sector data as context. For readers following Health stocks, here is Pluang's market snapshot as of Sep 21, 2026 20:01 WIB: out of 95 priced US Health stocks, 56 rose and 25 fell. Notable movers include CGC at USD 0.92 (-1.54%), DNA at USD 8.00 (+1.52%), and CLPT at USD 14.04 (+1.52%).
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Rothschild & Co Redburn raised Microsoft's price target from $400 to $440 following strong fiscal 2026 results, with revenue up 18% to $331.8 billion and net income rising 31% to $133.7 billion, driven by cloud and AI demand. Despite the target hike,...
